Zobrazeno 1 - 10 of 795 pro vyhledávání: '"E. Quoix"'
1
Akademický článek
O Cyfra 21-1 é um determinante prognóstico no carcinoma pulmonar não de pequenas células (CPNPC): resultado de uma meta-análise que incluiu 2063 doentes
Autor: J.-L. Pujol, O. Molinier, W. Ebert, J.-P. Daurès, F. Barlési, G. Buccheri, M. Paesmans, E. Quoix, D. Moro-Sibilot, M. Szturmowicz, J.-M. Bréchot, T. Muley, J. Grenier
Publikováno v: Revista Portuguesa de Pneumologia, Vol 10, Iss 6, Pp 518-520 (2004)
RESUMO: O objectivo da presente meta-análise foi determinar o valor prognóstico de níveis séricos pré-terapêuticos elevados de Cyfra 21-1, ajustados a co-variáveis clássicas no CPNPC.Baseou-se em elementos registados em bases
Externí odkaz: https://doaj.org/article/1ad2c2dad0864ee9bdaa79ef6a0189ba
Zobrazit plný text záznamu
3
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
Autor: O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette, S. Friard, I. Monnet, G. Jeannin, J. Mazières, J. Cadranel, J. Hureaux, W. Hilgers, E. Quoix, B. Coudert, D. Moro-Sibilot, E. Fauchon, V. Westeel, P. Brun, A. Langlais, F. Morin, P.J. Souquet, N. Girard
Publikováno v: ESMO Open
ESMO Open, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩
ESMO Open, European Society for Medical Oncology, 2022, 7 (1), pp.100353. ⟨10.1016/j.esmoop.2021.100353⟩
Background Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC). Materials a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca79719ac7e0d0d9f96b94dc3cb9c4f
https://hal.sorbonne-universite.fr/hal-03512207/document
Zobrazit plný text záznamu
4
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Autor: S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ETOP/IFCT 4-12 STIMULI Collaborators 2022, ' Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial ', Annals of Oncology, vol. 33, no. 1, pp. 67-79 . https://doi.org/10.1016/j.annonc.2021.09.011
Annals of Oncology, 33(1), 67-79. Oxford University Press
BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATI
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c0cd2636f83c5b87a3871c7a3d45ee
https://lirias.kuleuven.be/handle/123456789/682788
Zobrazit plný text záznamu
7
Les thérapies vaccinales dans le cancer bronchique
Autor: C. Leduc, E. Quoix
Publikováno v: Revue des Maladies Respiratoires. 36:415-425
Antigen-specific immunotherapy also known as cancer vaccination offers a novel approach for the treatment of non-small cell lung cancer patients. It relies on specific priming of the immune system in order to provoke or increase adaptive antitumor im
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a92dc709c5f569ed10b84de32626a275
https://doi.org/10.1016/j.rmr.2018.12.003
Zobrazit plný text záznamu
8
1827P European Society for Medical Oncology (ESMO)/International Society of Geriatric Oncology (SIOG) Joint Working Group (WG) survey on management of older patients with cancer
Autor: Laura Biganzoli, E. Quoix, Christopher Steer, V. Goede, Hans Wildiers, Etienne Brain, Demetris Papamichael, Siri Rostoft, Capucine Baldini, Ravindran Kanesvaran
Publikováno v: Annals of Oncology. 32:S1237-S1238
Background: ESMO and SIOG created a joint WG in 2019. Their goals are to improve management of the older cancer patients through education, dedicated resources and guidelines and to raise awareness on their specific needs and requirements. Therefore,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75c66c44be1e6946eb2c24ca016abb36
https://doi.org/10.1016/j.annonc.2021.08.715
Zobrazit plný text záznamu
10
Évaluation de la polymédication des patients âgés atteints de cancers bronchiques
Autor: B. Mennecier, P. Thomann, E. Quoix, N. Joret, Bénédicte Gourieux, Anne Gairard-Dory
Publikováno v: Le Pharmacien Hospitalier et Clinicien. 53:81-86
Resume La polymedication est responsable d’une augmentation du risque iatrogene, qui est aussi majore par des prescriptions inappropriees, notamment chez la personne âgee. Les patients âges representant plus de la moitie des patients diagnostique
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8aa3e97f94b064c7c334d6884c92e613
https://doi.org/10.1016/j.phclin.2017.10.061
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje